Subcutaneous injection of Factor XIIa antagonist monoclonal antibody (CSL312) 200 mg

2 trials

Sponsors

Akama Hideto

Conditions

Hereditary AngioedemaHereditary angioedema

Phase 3

CSL312 (garadacimab) in the prevention of hereditary angioedema attacks

Active, not recruitingJPRN-jRCT2031210056

Akama HidetoHereditary angioedema

Start: 2021-08-16Target: 60Updated: 2026-06-29

Long-term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks

Active, not recruitingJPRN-jRCT2031210328

Akama HidetoHereditary Angioedema

Start: 2021-11-10Target: 150Updated: 2026-06-29